NCT04085315 2024-06-10
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
University of California, San Francisco
Phase 1 Recruiting
Clinical Trials
3 trialsNCT04479306 2024-06-04
Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02367352 2019-06-26
Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors
Takeda
Phase 1 Terminated